Join Free For Buyer|Sign In

Professional Online Trade Platform for API, Preparation and Pharmaceutical Machinery and Equipment_EN-CPhI.cn

You are here:  Home >>  News >>  Editors’ Picks >>  Analysis of 39 New Biological Drugs Marketed in the World in 2018

Analysis of 39 New Biological Drugs Marketed in the World in 2018

February 01, 2019 By Xuanyao

21st century is the century of life sciences. Currently, more than half of members of the United States National Academy of Sciences engage in the life science field; more than half of the U.S. Federal Government’s budget for scientific research is used for life sciences. Therefore, biological drugs are developing faster and faster in human disease therapeutic areas, compared to chemical drugs.

Analysis of 39 New Biological Drugs Marketed in the World in 2018

Biotech drugs are referred to as biological drugs and mainly divided into recombinant protein drugs, recombinant polypeptide drugs, recombinant DNA drugs, and stem cell therapies, etc. It’s estimated that the global biological drug market will reach USD 326 billion in 2022. And Frost&Sullivan forecasts that the Chinese biological drug market will reach a size of RMB 326.9 billion in 2021. Among the 93 new drugs marketed in the world in 2018, there are 54 chemical drugs and 39 biological drugs.

Let’s check the targets and R&D information of those 39 drugs:

S/N

Pharmaceutical product name

Target

R&D company

1

Caplacizumab

vWF

Ablynx

2

Darvadstrocel (TiGenix)

unidentified

TiGenix, Takeda

3

YS-ON-001

unidentified

Yisheng Biopharma

4

Etanercept biosimilar (Mochida)

TNFβ, TNFα

Mochida Pharmaceutical , Ayumi

5

Adalimumab biosimilar

TNFα

Fujifilm Kyowa Kirin Biologics, Mylan

6

Adalimumab biosimilar

TNFα

Sandoz

7

Romosozumab

SO

Amgen, UCB, Astellas

8

Andexanet alfa

PT

Portola Pharmaceutical

9

Pegvaliase-pqpz

Phenylalanine

BioMarin Pharmaceutical

10

Cemiplimab

PD-1

Regeneron Pharmaceuticals , Sanofi

11

Sintilimab

PD-1

Innovent Biologics, Eli Lilly

12

Toripalimab

PD-1

Shanghai Junshi Biosciences, Suzhou Zhonghe

13

Velmanase alfa

Mannose

Zymenex

14

Lanadelumab

KLKB1

Dyax Pharma

15

Meningococcal A/C vaccine (Hualan Biological Bacterin)

Immunostimulator

Hualan Biological Bacterin Co., Ltd.

16

House-dust mite allergy immunotherapy (Lofarma)

Immunomodulator

Lofarma S.p.A, Ajou University School of Medicine

17

tagraxofusp-erzs

IL3RA

Texas A&M University, Stemline

18

Tildrakizumab-asmn

IL23

MSD, Sun Pharmaceutical, Almirall

19

Emapalumab

IFN-γ

NovImmune, SOBI

20

Recombinant cytokine gene derived protein (Genova Biotech)

IFNAR

Genova

21

Trastuzumab biosimilar (Allergan/Amgen)

HER2

Synthon, Allergan, Daiichi Sankyo, Amgen

22

Trastuzumab biosimilar (Pfizer)

HER2

Pfizer

23

Agalsidase beta biosimilar (JCR Pharmaceuticals)

Glycosphingolipid

JCR Pharmaceuticals

24

Condoliase (Seikagaku corporation)

GAG

Seikagaku, Kaken Pharmaceutical Co., Ltd., Ferring Pharmaceuticals

25

Burosumab-twza

FGF23

Kyowa Hakko Kirin, Ultragenyx

26

Damoctocog alfa pegol

F10

Bayer

27

Mecapegfilgrastim

CSF3R

Jiangsu Hengrui

28

Pegfilgrastim biosimilar (Cinfa Biotech)

CSF3R

Cinfa Biotech, Mundipharma

29

Pegfilgrastim biosimilar (Sandoz)

CSF3R

Sandoz

30

Pegfilgrastim-cbqv (Coherus BioSciences)

CSF3R

Coherus Biosciences

31

Pegfilgrastim-jmdb

CSF3R

Biocon, Mylan

32

Fremanezumab

CGRP

Pfizer, Teva

33

Galcanezumab

CGRP

Eli Lilly

34

Ibalizumab-uiyk

CD4

Biogen, TaiMed Biologics, Theratechnologies

35

Moxetumomab pasudotox

CD22

AstraZeneca

36

Erenumab-aooe

CALCRL

Amgen, Novartis

37

Ravulizumab

C5

Alexion Pharmaceuticals

38

Calaspargase pegol

ASN

Shire, Servier

39

Elapegademase-lvlr

Adenosine

Leadiant Biosci

According to the forecast of IMS Health, the Chinese biopharmaceutical market will become the world’s second largest biopharmaceutical market in 2020, only next to the U.S. Then, what are the forefronts in the process? How can pharmaceutical practitioners reach new heights?

Xuanyao, an independent observer of the pharmaceutical industry, with a master’s degree in Pharmacology from China Pharmaceutical University; having successively served in the Market Department of a listed pharmaceutical enterprise in China and Marketing Department of a Global 500 foreign enterprise; currently engaging in the pharmaceutical private equity investment industry, with the WeChat account: pharmacology_cpu

Register as Visitor to CPhI China 2019!

Register as Visitor to CPhI China 2019!

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.

 

Readers'Comments
Add a comment
Click here to Login or to Register for free. You will be taken back to your selected item after Login/Registration.
More>> MarketNews
More>> Editors’Picks
More>> TopStories
More>> HotTags
Follow Us
CPhI Online Trade Platform: Worldwide|English|中国站
Customer Service:  86-400 610 1188 (9: 00-18: 00, Mon-Fri)
About Us| Contact Us| Terms of Services| Privacy Policy| Intellectual Property Statement| Links | Site Map
Copyright 2006-20 Shanghai Sinoexpo Informa Markets International Exhibition Co. Ltd (All Rights Reserved). ICP 05034851-53
客服
live chat